Grants and Contributions:
Title:
Lead Optimization Studies-Phase II
Agreement Number:
953841
Agreement Value:
$136,500.00
Agreement Date:
Jul 1, 2020 - Mar 31, 2021
Description:
A lead optimization study to define a clinical candidate amongst a novel series of GPR119 agonists for the treatment of Type2 Diabetes and co-morbidities. This study has the potential to lead to the development of a first in class therapeutic for T2DM and obesity and advancement of a novel therapeutic pipeline to address co-morbidities associated with GPR119 dysregulation including NASH.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V6C 3P1
Reference Number:
172-2020-2021-Q2-953841
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
801099599
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is 21,500 dollars.
Amendment Date
Feb 17, 2021
Recipient's Legal Name:
Pramana Pharmaceuticals Inc.
Federal Riding Name:
Vancouver Centre
Federal Riding Number:
59034
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410
Amendments: